# Neutralization of Primate Immunodeficiency Viruses

> **NIH NIH R01** · WEILL MEDICAL COLL OF CORNELL UNIV · 2020 · $177,065

## Abstract

We will repurpose existing assays, techniques and expertise that are central to our project team’s virology, structural biology, vaccine development and protein production skill-sets for HIV research, to now also work on SARS-CoV-2 during the COVID-19 pandemic emergency. These interactive research efforts will draw on our established methodologies and should represent a productive use of our existing NIH grant resources. We note that there continue to be institutional restrictions at all three performance sites on the effort that can be applied to our original goals relating to HIV-1 vaccine research and development. Those goals will be unchanged, but will be pursued at a reduced effort during the period when we also work on the new SARS-CoV-2 projects for which we have fewer institutional restrictions due to the COVID-19 pandemic.

## Key facts

- **NIH application ID:** 10226628
- **Project number:** 3R01AI036082-28S1
- **Recipient organization:** WEILL MEDICAL COLL OF CORNELL UNIV
- **Principal Investigator:** JOHN P MOORE
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $177,065
- **Award type:** 3
- **Project period:** 1994-05-01 → 2023-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10226628

## Citation

> US National Institutes of Health, RePORTER application 10226628, Neutralization of Primate Immunodeficiency Viruses (3R01AI036082-28S1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10226628. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*